IRVINE, Calif., and REHOVOT, Israel, Feb. 2, 2016 /PRNewswire/ — OticPharma, Ltd., a privately held specialty pharmaceutical company focused on acquiring and developing innovative therapies for ear, nose, and throat (ENT) disorders, today announced that Gregory J. Flesher, chief executive officer, will present an overview of the company at the upcoming 18th Annual BIO CEO & Investor Conference to be held at the Waldorf Astoria Hotel in New York, NY.
- Date: Monday, February 8, 2016
- Time: 2:30 p.m. Eastern Tim
- Room: Park North, Waldorf Astoria Hotel
Investors or potential partners attending the conference who wish to meet with the company during the conference should contact the BIO Partnering team at firstname.lastname@example.org.
OticPharma is a clinical-stage pharmaceutical company focusing on the development of ear, nose, and throat (ENT) products that restore health and address unmet needs in children and adults. The company’s proprietary foam technology (OP-01) is currently being developed for acute otitis externa (“swimmers ear”) and is also being explored for nasal and sinus uses. The company’s proprietary surfactant technology (OP-02) is currently being developed as a potential first-in-class, antibiotic-free treatment option for acute, recurrent, and chronic otitis media.
Investor and Media Contact
The Trout Group
Tel: +1 (646) 378-2949
Gregory J. Flesher
Tel: +1 (949) 238-8090